15 results on '"Rybicki, Lisa A."'
Search Results
2. Characteristics of Patients with Cancer Readmitted Within 30 Days to an Acute Palliative Care Unit.
- Author
-
El Hachem, Pierre, Pasniciuc, Silviu, Khurana, Saurabh, Samala, Renato V., Rybicki, Lisa A., Lagman, Ruth L., and Davis, Mellar P.
- Subjects
CANCER patients ,PATIENT readmissions ,PALLIATIVE treatment ,THROMBOEMBOLISM ,HOSPITAL care - Abstract
Objective(s): For patients with cancer, the emergence of acute palliative care units (APCU) may hold promise in curtailing hospital readmissions. The study aims to describe the characteristics of patients readmitted to an APCU. Methods: This retrospective study examined patients with cancer readmitted within 30 days to an APCU. Readmissions were further classified as either potentially preventable or non-preventable. Results: Out of 734 discharges from July 1, 2014 to July 1, 2015, 69 (9%) readmissions were identified and analyzed. For index admissions, median length of stay was five days, and one (1%) was discharged home with hospice care. For readmissions, median time from index admission to readmission was nine days, median length of stay was six days, three (4%) patients died, and 20 (30%) went home with hospice. Ten (14.5%) readmissions were deemed potentially preventable (95% CI 7.2-25.0%). Race/ethnicity—White/Black/Hispanic/Others—was 60%, 10%, 20% and 10%, respectively, among potentially preventable readmissions and 76%, 22%, 2% and 0%, respectively, among potentially non-preventable readmissions (P =.012). Potentially preventable readmissions were more likely to have venous thromboembolism (40% vs. 12%, P =.046) and more reasons for readmission (median 2 vs. 1, P =.019). Conclusions: Among patients with cancer readmitted to an APCU, one out of seven was potentially preventable and a far larger proportion was discharged with hospice care compared to the index admission. Recognition of disease course, meaningful goals of care discussions and timely transition to hospice care may reduce rehospitalization in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Symptom clusters and prognosis in advanced cancer
- Author
-
Aktas, Aynur, Walsh, Declan, and Rybicki, Lisa
- Published
- 2012
- Full Text
- View/download PDF
4. Symptom clustering in advanced cancer
- Author
-
Walsh, Declan and Rybicki, Lisa
- Published
- 2006
- Full Text
- View/download PDF
5. Symptom evaluation in palliative medicine: patient report vs systematic assessment
- Author
-
Homsi, Jade, Walsh, Declan, Rivera, Nilo, Rybicki, Lisa A., Nelson, Kristine A., LeGrand, Susan B., Davis, Mellar, Naughton, Michael, Gvozdjan, Dragoslav, and Pham, Hahn
- Published
- 2006
- Full Text
- View/download PDF
6. Underrecognition of Malnutrition in Advanced Cancer: The Role of the Dietitian and Clinical Practice Variations.
- Author
-
Aktas, Aynur, Walsh, Declan, Galang, Marianne, O’Donoghue, Niamh, Rybicki, Lisa, Hullihen, Barbara, and Schleckman, Ellen
- Abstract
Introduction: Malnutrition (MN) often goes unrecognized due to ineffective screening techniques. Published standards for multidisciplinary care exist but no consensus on best nutritional assessment for hospitalized patients. Malnutrition is common in cancer and adversely affects clinical outcomes. The Cleveland Clinic Nutrition Therapy Department used in-house criteria to classify MN in hospitalized patients. This study aimed to evaluate the registered dietitian (RD)’s role, the use of these criteria in the acute care palliative medicine unit (ACPMU), and investigate MN prevalence and severity among admitted patients with cancer. Methods: Electronic medical records were reviewed for newly admitted patients with cancer to the ACPMU with a first time RD consult and completed nutritional therapy assessment. Physician (MD) assessments were derived from admission notes. Cox regression model assessed the association of MN prevalence and severity with survival. McNemar’s test determined whether a prevalence difference existed between RD and MD. Results: Variations existed in criteria used to identify MN. Seventy percent had MN, with the majority (61%) classed as moderate to severe. Prevalence (hazard ratio [HR]: 1.88; P = .002) and severity (HR: 1.22; P = .006) were associated with significantly increased mortality. Evaluations by RD and MD were highly congruent, but MDs underrecorded nutritional status. Conclusion: Malnutrition was prevalent and clinically important, even in those on nutritional support. Variations in MN identification were common. Physicians underrecorded MN but were accurate for prevalence and severity when recorded. The data confirm the RD’s important role in MN assessment. Comparable clinical practice and better communication between physicians and dietitians should improve cancer care and optimize quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. What’s in a Name? Word descriptors of cancer-related fatigue.
- Author
-
Hauser, Katherine, Rybicki, Lisa, and Walsh, Declan
- Subjects
- *
TUMOR classification , *CANCER complications , *CANCER patients , *DEMOGRAPHY , *RESEARCH methodology , *FATIGUE (Physiology) , *ONCOLOGY , *PALLIATIVE treatment , *TUMORS , *DATA analysis , *DISEASE complications , *DIAGNOSIS , *CANCER treatment , *THERAPEUTICS - Abstract
Many different words are used to describe fatigue. It is unclear whether these word descriptors represent the same cancer symptom or dimension. The objective of this study was to identify clinical associations of three fatigue word descriptors (FWDs): ‘easy fatigue’, ‘weakness’, and ‘lack of energy’ (LOE). One thousand consecutive palliative medicine patients completed a 38-item symptom checklist. The prevalence of the three FWDs alone and in combination was calculated. Spearman correlations assessed associations between FWDs. Logistic regression analysis identified univariable and multivariable predictors for each FWD. Survival was estimated using the Kaplan—Meier method, individually and for 0—1 versus 2—3 FWDs, and compared using log-rank tests.The prevalence of easy fatigue was 69%, weakness 66%, and LOE 61%. Correlations between the FWDs were high (0.65—0.79). In multivariable models, clinical associations (particularly neuro-psychiatric symptoms and performance status) of the FWDs were variable. Weakness was associated with performance status, but not anxiety or depression. LOE was associated with anxiety and depression, but not performance status. Fatigue was associated with depression, but not anxiety or performance status. All FWDs were associated with dry mouth, early satiety, sleep problems, and weight loss. The worst survival was associated with two or three reported FWDs compared with none or one (P < 0.001). Weakness and LOE had distinct clinical associations that differed from fatigue. Evaluation of fatigue should use multiple descriptors (particularly weakness), as they are not synonymous. Further research is necessary to identify biological associations for discrete FWDs. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. Symptom clusters: myth or reality?
- Author
-
Aktas, Aynur, Walsh, Declan, and Rybicki, Lisa
- Subjects
PALLIATIVE treatment ,ETIOLOGY of diseases ,CANCER ,NAUSEA ,VOMITING - Abstract
Clinical experience suggests that many symptoms occur together. In this paper, we examine the rationale and evidence base for symptom clusters in different medical fields, particularly the cluster phenomenon in cancer. Cancer symptom clusters are a reality. Various symptoms that cluster clinically have also been verified statistically. Specific clusters such as nausea-vomiting, anxiety-depression, and cough-dyspnea are evident on both clinical observation and in research investigation. Fatigue-pain and fatigue-insomnia-pain have also been demonstrated statistically as clusters. Another proposed cluster 'depression-fatigue-pain' seems relevant to clinical practice. Other clusters may serve only as theoretical models that illustrate possible common biological etiologies in cancer; they need to be validated in future research. Analysis of the literature is complicated by considerable inconsistencies across studies. Discrepancies between clinically defined and statistically obtained clusters raise important questions. We must consider the analytical techniques used, and how methodology might influence cluster occurrence and composition. Further research is warranted to establish universally accepted statistical methods and assessment tools for symptom cluster research. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. A Comparative Study of 2 Sustained-Release Morphine Preparations for Pain in Advanced Cancer.
- Author
-
Homsi, Jade, Walsh, Declan, Lasheen, Wael, Nelson, Kristine A., Rybicki, Lisa A., Bast, Jane, and LeGrand, Susan B.
- Abstract
Purpose: Several sustained-release morphine (SRM) formulations are available internationally. This study compared 2 such products available in the United States, SR1 and SR2. Patients and Methods: In an open-label study, patients with advanced cancer pain were randomized to receive SR1 or SR2 every 12 hours around-the-clock (ATC) for 5 days, with immediate release (IR) liquid morphine for rescue dosing (RD). Efficacy, safety, and patient acceptability were determined. Results: A total of 32 patients were evaluable for efficacy and toxicity. Pain scores, RD dosage, RD frequency over 5 days, RD within 3 hours before and after the scheduled SRM, and 8 of the 11 evaluated side effects were higher in the SR1 group. At presumed morphine steady state (day 3), pain scores (P = .05), RD dosage (P = .07), RD frequency (P = .07), and number of RD ± 3 hours from scheduled SRM dose (P = .05) were consistently greater in the SR1 group (despite a higher median morphine dose in that group). There was a clinically important and directionally consistent trend that favored SR2, although not all were statistically significant. Patient preference favored SR2 (P < .05). Neither group had difficulty swallowing SR1 or SR2. Conclusions: This is the first study that directly compared two 12-hour SRM formulations. The data suggested, by multiple clinically important measures, that SR2 may provide superior analgesic efficacy and less toxicity compared to SR1. It also supports the concept that it cannot be assumed that different SR formulations of a given opioid are clinically equivalent. A larger study is needed to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
10. Respiratory function during parenteral opioid titration for cancer pain.
- Author
-
Estfan, Bassam, Mahmoud, Fade, Shaheen, Philip, Davis, Mellar P., Lasheen, Wael, Rivera, Nilo, LeGrand, Susan B., Lagman, Ruth L., Walsh, Declan, and Rybicki, Lisa
- Subjects
PULMONARY function tests ,CANCER pain ,INDICATORS & test-papers ,OPIUM ,PARENTERAL solutions - Abstract
Background: Respiratory depression is the most feared opioid-related side-effect yet research on the topic is sparse. We evaluated changes in respiratory parameters during parenteral opioid titration for cancer pain to determine if opioid titration was associated with evidence of hypoventilation. The primary outcome measure was to measure changes in end-tidal CO
2 (ET-CO2 ) during opioid titration to pain control. Methods: Subjects with severe cancer pain admitted for parenteral opioid titration for poorly controlled pain were eligible. Those who were oxygen dependent were excluded. ET-CO2 , O2 saturation, respiratory rate (RR), and vital signs were monitored daily until pain control was achieved. Results: 30 patients completed the study of which 29 are reported. The mean ET-CO2 at initial evaluation was 33.39±5.0 and 34.79±5.7 mmHg at pain control (P=0.14, 95% CI -0.5 to 3.3). None had an ET-CO2 ⩾50 mmHg. All maintained O2 saturation ⩾92%. RR dropped transiently below 10/minute in two subjects. Conclusions: Parenteral opioid titration for relief of cancer pain was not associated with respiratory depression as demonstrated by significant changes in ET-CO2 or oxygen saturation in non-oxygen dependent cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
11. Survival of Patients who have Undergone Allogeneic Bone Marrow Transplantation: The Relative Importance of In-Hospital Lay Care-Partner Support.
- Author
-
Foster, Larry W., McLellan, Linda J., Rybicki, Lisa A., Sassano, Deborah A., Hsu, Amy, and Bolwell, Brian J.
- Abstract
Data from 131 consecutive adult patients who underwent allogeneic bone marrow transplantation (BMT) at a tertiary care center from 1997 to 1999 suggest that the presence of an in-hospital lay care-partner during the patients' hospital stay is a powerful prognostic variable of survival. One year after the transplant, 75% of the patients with a lay care-partner were alive versus 26% of those without a care-partner. A multivariable survival analysis revealed not having an in-hospital lay care-partner as a significant independent risk factor for death (p <.001). This relationship held when adjusting for other such risk factors: i.e., primary diagnosis, disease status, and source of donor marrow. The idiosyncratic nature and importance of partnered relationships for survival in allogeneic BMT and the need to intervene and improve outcomes for patients are discussed with regard to future research and clinical programs. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
12. Gastrointestinal symptoms among inpatients with advanced cancer.
- Author
-
Komurcu, Seref, Nelson, Kristine A., Walsh, Declan, Ford, Rashawn Bradley, and Rybicki, Lisa A.
- Abstract
Nearly one-half of the most frequently reported and most distressing symptoms in patients with advanced cancer are gastrointestinal in nature. This prospective study was designed to assess the frequency of gastrointestinal symptoms among inpatients admitted to a palliative medicine program with advanced cancer.Twenty-nine men and 21 women, with a median age of 64 years (range, 35-84), were interviewed about 17 gastrointestinal symptoms. Age, gender, diagnosis, and medication use were also recorded.The most common diagnoses were cancers of the lung (n = 14), breast (n = 6), and prostate (n = 4). Dry mouth (84 percent), weight loss (76 percent), early satiety (71 percent), taste change (60 percent), constipation (58 percent), anorexia (56 percent), bloating (50 percent), nausea (48 percent), abdominal pain (42 percent), and vomiting (34 percent) were the 10 most common gastrointestinal symptoms. Women had more gastrointestinal symptoms than men (median 8 vs. 6, p = 0.018), although this finding was not statistically significant (p = 0.11) after excluding gender-specific cancers. Women had more taste change and diarrhea than men after excluding gender-specific cancers (p = 0.036 and p = 0.046, respectively). Those with primary gastrointestinal cancers (n = 8) had more indigestion and hiccups than those with nongastrointestinal cancers (n = 39). There was no age difference in symptomatology. The drugs prescribed most commonly were opioids (n = 40), laxatives (n = 38), H2 blockers (n = 29), appetite stimulants (n = 29), and antiemetics (n = 29).Findings support that gastrointestinal symptoms are very common in hospitalized patients with advanced cancer and that the frequency and type of symptoms differ with gender and gastrointestinal vs. nongastrointestinal primary site. [ABSTRACT FROM PUBLISHER]
- Published
- 2002
- Full Text
- View/download PDF
13. A phase II study of methylphenidate for depression in advanced cancer.
- Author
-
Homsi, Jade, Nelson, Kristine A., Sarhill, Nabeel, Rybicki, Lisa, LeGrand, Susan B., Davis, Mellar P., and Walsh, Declan
- Abstract
This study evaluated the use of methylphenidate for depression in advanced cancer.Design:Phase II open-label prospective study.Eligibility criteria:No previous use of methylphenidate or current use of other antidepressants.Evaluation:Depression and response to treatment were determined by asking the patient: “are you depressed?” Patients were assessed at baseline and at days 3, 5, and 7.Treatment:Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days.Response criteria:A negative response to the question: “are you depressed?”Results:Some 41 patients were enrolled and 30 (15 men, 15 women) completed the study. Median age was 68 years (range: 30-90). Methylphenidate was stopped for six patients because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5; 29 maintained their positive response through day 7. Anorexia, fatigue, concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop.Conclusions:Methylphenidate is effective for depression in advanced cancer. A starting dose of 10 mg in divided doses is effective in most patients. Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended. [ABSTRACT FROM PUBLISHER]
- Published
- 2001
- Full Text
- View/download PDF
14. Predicting outcomes in patients with cancer and atrial fibrillation.
- Author
-
Gutierrez, Alejandra, Patell, Rushad, Rybicki, Lisa, and Khorana, Alok A.
- Abstract
Background: The role of cancer-specific factors for ischemic stroke and mortality in patients with cancer and atrial fibrillation (AF) is unknown. We evaluated the utility of a previously validated risk tool for venous thromboembolism (VTE) in cancer outpatients [Khorana score (KS)] in predicting stroke and mortality in cancer patients with AF. Methods: We conducted a retrospective cohort study of patients with cancer and AF at the Cleveland Clinic from 2008 to 2014. Outcomes, CHADS2, CHA2DS2-VASc, and KS scores were calculated from date of cancer diagnosis. Prognostic factors were identified with Fine and Gray regression (for stroke) or Cox proportional hazards analysis (for mortality). Results: The study population comprised 1181 patients. Genitourinary (19%), lung (18%), and gastrointestinal (13%) were the most frequent cancers. Overall, 67% had CHADS2 ⩾ 2, 57% had an intermediate KS (1–2), and 7% high KS (⩾3). Median follow up was 26.5 months (range 0.03–76). At a median of 8.2 months (range 0–61), 45 patients (3.8%) developed a stroke and 418 (35%) died. In multivariable analysis a high KS (HR 4.5, 95% CI 3.2–6.3, p < 0.001) was associated with a quadruple risk of death and every point increase in CHADS2 score had a 20% increased risk of death (HR 1.19, 95% CI 1.1–1.2, p < 0.001). The addition of KS did not improve risk stratification for ischemic stroke to CHADS2. Conclusion: In patients with cancer and AF, CHADS2 and CHA2DS2-VASc but not KS were predictive of ischemic stroke. A high KS represented a unique predictor of mortality beyond traditional risk scores. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Is FDG-PET indicated for superficial esophageal cancer?
- Author
-
Little, Sherard G., Rice, Thomas W., Bybel, Bohdan, Mason, David P., Murthy, Sudish C., Falk, Gary W., Rybicki, Lisa A., and Blackstone, Eugene H.
- Subjects
- *
CANCER , *POSITRON emission tomography , *TUMORS , *METASTASIS - Abstract
Abstract: Objective: To ascertain whether fluorodeoxyglucose positron emission tomography is indicated for clinical staging of superficial cancer, we sought to determine if it accurately classifies tumor (T), regional nodal (N), and distant metastases (M), including distinguishing high-grade dysplasia (Tis) from invasive cancer (T1). Methods: Fifty-eight superficial esophageal cancer patients had preoperative positron emission tomography, 53 (91%) fused with computed tomography. Tumor characteristics, esophagoscopy findings, and pTNM were compared with positron emission tomography cTNM. pT1 was subdivided into intramucosal cancers with lamina propria or muscularis mucosa invasion and submucosal cancers with inner or outer invasion. Results: Fluorodeoxyglucose uptake increased with pT, from 5/11 (45%) for pTis to 11/16 (69%) for pT1 (outer submucosa), P =0.07, as it did for standardized uptake value, median 0 for pTis to 2.7 for pT1 (outer submucosa), P =0.06. Positron emission tomography could not differentiate Tis (5/11, 45%) from T1 (26/47, 55%; P = 0.03). Regional nodal fluorodeoxyglucose uptake in three patients (standardized uptake value 2.8, 4.9, 11) was false positive; in six pN1 patients, it was false negative. Positron emission tomography had 0% sensitivity and positive predictive value for N1. There were no distant metastases; one patient developed a pulmonary metastasis 15 months postoperatively. Positron emission tomography detected three (5%) distant hypermetabolic sites, all synchronous tumors (papillary thyroid cancer, adrenal pheochromocytoma, rectal adenoma). Only increasing tumor length was related to greater fluorodeoxyglucose uptake (P = 0.004) and higher standardized uptake value (P = 0.001). Conclusions: Because positron emission tomography can neither differentiate pTis from T1 nor classify T, N, and M, it is not indicated in staging superficial esophageal cancer. Finding a synchronous primary tumor in approximately every 20th patient is its only benefit. Better, less expensive screening tools are available for common synchronous malignancies. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.